#1INOVIO Powering a New Decade of DNA Medicines POWERING DNA MEDICINES™ September 2020 Nasdaq:INO#22 Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design," "estimate,” “predict," "opportunity," "proposition," "strategy,” “potential," "plan" or the negative of these terms and similar expressions intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the scope, progress, expansion and costs of developing and commercializing our product candidates; our expectations regarding the amount and timing of our expenses and revenue; the sufficiency of our cash resources, plans for the use of our cash resources and needs for additional financing; our ability to adequately manufacture our product candidates; our ability to obtain and maintain intellectual property protection for our product candidates; our expectations regarding competition; the size and growth of the potential markets for our product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of our product candidates; our anticipated growth strategies; the anticipated trends and challenges in our business and the market in which we operate; our ability to establish and maintain development partnerships; our ability to attract or retain key personnel; our expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our Annual Report on Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, which have been filed with the Securities and Exchange Commission (SEC) and are available on the SEC's website at www.sec.gov. In addition, the forward-looking statements included in this presentation represent INOVIO's views as of the date hereof. INOVIO anticipates that subsequent events and developments may cause its views to change. However, while INOVIO may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing INOVIO's views as of any date subsequent to the date of this presentation. Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information has not been independently verified by, and should not be construed as a representation by, INOVIO. The information contained in this presentation is accurate only as of the date hereof. "Inovio" and the Inovio logo are trademarks and service marks of INOVIO. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners. INOVIO POWERING DNA MEDICINES#33 Powering a New Decade of DNA Medicines Precisely Designed Plasmids Delivered Through Proprietary Smart Device Safe and Robust Immune Responses in More Than 2,000 Patients DNA VACCINES FIRST & ONLY COVID-19 Vaccine to Show Long-Term Protection Against Live Virus in NHPs 13-Weeks Post-Vaccination (INO-4800) FIRST Vaccine to Generate Immune Response Against COVID-19 Variant D614G (INO-4800) SADIDINE INOVIO In Vivo Immune Responses for "Off-the-Shelf" Speed, Efficiency Extensive Patent Portfolio Protecting Technology Platform DNA IMMUNOTHERAPIES FIRST to Show Clearance of High-Risk HPV 16/18 in Phase 2b Trial (VGX-3100) FIRST DNA Medicine in Phase 3 Clinical Trials (VGX-3100 for Precancerous Cervical Dysplasia) FIRST Vaccine in Phase 2 for Middle East Respiratory Syndrome (INO-4700) FIRST DMAb TM Plasmid in Phase 1 for Zika (INO-A002) FIRST to Show Complete Response in Phase 1 w/2 PD-1s for Head and Neck Cancer (MEDI0457) FIRST DNA Medicine to Show Potential for Efficacy in GBM (INO-5401) INOVIO POWERING DNA MEDICINES#44 INOVIO Vision to Build the Leading DNA Medicine Company • • . Founding Vision Create precisely designed plasmids that target antigens to address urgent medical needs Develop proprietary device to deliver plasmid safely in vivo directly into the cell to produce robust immune response Build scientific, medical, and commercial team and outstanding partnerships to drive value • • Near-Term Execution Rapidly bring to market precisely designed DNA medicines to potentially treat and prevent diseases associated with HPV, cancer, and infectious diseases Maximize value of lead candidates worldwide . • Long-Term Strategy Create new market in safe, effective DNA medicines Aggressively seek partners to ensure DNA medicines reach patients in need Strong financial position • $371.7M cash/investments as of last reported earnings (6/30/20) INOVIO POWERING DNA MEDICINES#5Vision Built on INOVIO Proprietary Technology OPTIMIZED PLASMID DESIGN AND DELIVERY TECHNOLOGY PRECISELY DESIGNED PLASMIDS (SynCon®) PROPRIETARY SMART DEVICE (CELLECTRA®) 14 5 LO IN VIVO INOVIO POWERING DNA MEDICINES#6CO 6 INOVIO Technology - Powering Potent Antigen Specific Immune Responses 1. Identify diverse strains/variants of a target virus or cancer Antigen Y Strain 2 INOVIO DNA medicines power a patient's immune system to generate functional antibodies and killer T cells in vivo to fight cancer and infectious disease 2. Assess gene sequence of selected antigen(s) from chosen strains/variants of the virus or cancer 3. Create optimal Consensus Sequence for the selected antigen 4. Insert SynCon sequence for each selected antigen into a separate precisely designed plasmid 5. Manufacture DNA medicine and deliver into muscle (IM) or skin (ID) using CELLECTRAⓇ proprietary smart device Antigen Y Antigen Y Strain X Strain 1 6. Protective antibodies and killer T cells produced by immune system against diverse strains of a virus or cancer Sequence 1 EMEKIVLLFAIV...SL XX Sequence 2 Sequence X Consensus AMESIVLLFAIV...SL DNA Medicine DNA Medicine AMEKIVILLFAIV...SK AMEKIVILLFAIV...SL INOVIO IM ID INOVIO POWERING DNA MEDICINES#77 INOVIO's Technology Advantages Clinical Efficacy Demonstrated clinical efficacy in Phase 2b study Lead candidate VGX-3100 in Phase 3 for precancerous cervical dysplasia Safety • Favorable safety profile tested in over 2,000 patients and over 7,000 administrations Carries no potential toxicity from viral vectors Versatility and Boosting • • Targets virtually any antigenic sequence; combining multi-antigens into single vial Initiated first-in-human study of optimized dMAb TM plasmid No anti-vector response - allows for effective boosting Rapid and Scalable Manufacturing • • "Off-the-shelf" product; no frozen storage issues (room temp storage >1 yr.) Rapid development from concept to human in <3 months (COVID-19 vaccine) Relatively inexpensive to manufacture; produce large quantities INOVIO POWERING DNA MEDICINES#8INOVIO DNA Medicines Pipeline 8 PRODUCT HPV-TARGETED VGX-3100 INO-3107 INDICATION Precancerous Cervical Dysplasia (HSIL) Precancerous Vulvar Dysplasia (HSIL) Precancerous Anal Dysplasia (HSIL) Recurrent Respiratory Papillomatosis (RRP) ANTIGEN PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNER/COLLABORATOR/FUNDER HPV 16 E6, E7/ HPV 18 E6, E7 HPV 6 E6, E7/ HPV 11 E6, E7 Head & Neck Cancer MEDI0457 HPV 16 E6, E7/ HPV 18 E6, E7 Cervical, Anal, Penile, Vulvar Cancers IMMUNO-ONCOLOGY (NON HPV-ASSOCIATED) INO-5401 Glioblastoma Multiforme (GBM) WT1, PSMA, hTERT INO-5151 Prostate Cancer PSA, PSMA INTERNALLY FUNDED Apollobio (China; INOVIO maintains global rights) AstraZeneca REGENERON CANCER RESEARCH INSTITUTE PICI PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY EXTERNALLY FUNDED INOVIO POWERING DNA MEDICINES#99 INOVIO DNA Medicines Pipeline (Continued) PRODUCT INDICATION ANTIGEN PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INFECTIOUS DISEASES (NON HPV-ASSOCIATED) PENNVAX-GP HIV Gag, pol, env INO-4201 Ebola INO-4700 MERS (GLS-5300) INO-4600 Zika (GLS-5700) Glycoprotein Spike Glycoprotein INO-4500 Lassa Fever Glycoprotein INO-4800 COVID-19 (Coronavirus) TM dMAb™ (DNA-ENCODED MONOCLONAL ANTIBODIES) INO-A002 Zika Spike Glycoprotein INTERNALLY FUNDED PARTNER/COLLABORATOR/FUNDER NIH NIAID HIV VACCINE TRIALS NETWORK DARPA GENE CEPI GENE CEPI CEPI BILL&MELINDA GATES foundation BILL& MELINDA GATES foundation EXTERNALLY FUNDED INOVIO POWERING DNA MEDICINES#1010 Infectious Disease Programs#1111 Key Characteristics of INOVIO's DNA Vaccine Platform Refrigerated (2-8°C) Storage >5 years 2-8°C 0000 0000 >5 YEARS Room Temp (25°C) Storage >1 year; 37°C 2 months 25°C 37°C 00 000 >1 YEAR >2 MONTHS SynConⓇ Rapid & Scalable Manufacture 0000 ooooooo 0000 SynConⓇ Rapid Design Robust Immune Responses (Neutralizing anti-bodies/ B cells and Killer T cells) CELLECTRAⓇ Multi-antigen Immunotherapy/ Protection in Single Vial Host DNA Plasmids Non-replicating, Non-integrating No Anti-Vector Response (effective boosting) INOVIO POWERING DNA MEDICINES#1212 Infectious Disease Platform: Positive Clinical Data and Partnering Opportunities Product Indication Data Reported (to date) Partner/s PENNVAX-GP HIV Phase 1: 93% (71 of 76) evaluable vaccinated participants showed a CD4+ or CD8+ cellular immune response to at least one of the vaccine antigens NIH NIAID HIV VACCINE TRIALS NETWORK INO-4201 Ebola • INO-4700 (GLS-5300) INO-4600 (GLS-5700) MERS Zika • • 94% (62 of 66) demonstrated an env specific antibody response Phase 1: High levels of binding antibodies measured (ELISA) in 95% (170 of 179) of evaluated subjects Published: The Journal of Infectious Diseases, March 2019 Phase 1: High levels of binding and neutralizing antibodies in >90% of subjects • 98% generated an antibody and/or T cell response against MERS Published: The Lancet Infectious Diseases, July 2019 . • • Presented: ASGCT, May 2020 Phase 1: High levels of binding antibodies measured (ELISA) in 100% (39 of 39) of evaluated subjects Published: New England Journal of Medicine, October 2017 DARPA Next Milestone Interim results from Phase 1/2 HIV trial study 2020 (UCSF; Deeks) Seeking additional grant funding for Phase 2 development Initiate Phase 2 clinical trial 진원생명과학(주) GENE in Middle East GeneOne Life Science CEPI GENE 진원생명과학(주) GeneOne Life Science Report on Puerto Rico study 2020 INOVIO POWERING DNA MEDICINES#13INOVIO'S COVID-19 DNA Vaccine INO-4800 Development Timeline DECEMBER 2019 INOVIO coronavirus experts learn about a novel coronavirus (SARS-COV-2) that caused an outbreak of respiratory disease in Wuhan, China, now referred to as COVID-19 JANUARY 10/11, 2020 Chinese researchers share the genetic sequence of the novel coronavirus on 1/10 INOVIO designs DNA vaccine INO-4800 in three hours after receiving the genetic sequence late in the evening on 1/10 using its proprietary DNA medicines platform technology INO-4800 was designed just after midnight on 1/11 to precisely match the DNA sequence of the virus JANUARY 10 - JANUARY 23, 2020 INOVIO coronavirus experts race to manufacture INO-4800 and begin preclinical testing and clinical trial design JANUARY 23, 2020 INOVIO receives a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund ongoing preclinical and initial clinical development of INO-4800 CEPI MARCH 2020 Ongoing preclinical studies, including challenge studies; human clinical trial designs finalized; 3,000 human trial doses prepared for clinical trials in the U.S., China, and South Korea; large-scale manufacturing plans developed MARCH 12, 2020 INOVIO announces $5 million grant from the Bill & Melinda Gates Foundation to continue advancing the development of INO-4800, specifically to accelerate the testing and scale up of INOVIO's proprietary smart device CELLECTRA® 3PSP BILL & MELINDA GATES foundation MARCH 26, 2020 APRIL 6 - APRIL 23, 2020 INOVIO announces the Department of Defense (DoD) awarded Ology Bioservices an $11.9 million contract to work with INOVIO on DNA technology transfer to rapidly manufacture INO-4800 for the DoD for upcoming clinical trials HMENT PARTME OF INOVIO announces initiation of Phase 1 human clinical trial in the U.S. following authorization by the U.S. Food and Drug Administration of its Investigational New Drug (IND) application U.S. study fully enrolls 40 healthy volunteers; study sites are the University of Pennsylvania and a clinic in Kansas City, MO MAY 20, 2020 Preclinical data (in mice and guinea pigs) published in peer-reviewed journal Nature Communications nature. COMMUNICATIONS Clinical trials and preclinical challenge studies continue JUNE/JULY 2020 Phase 1 trial expanded with 80 additional participants (older adults, low-dose arm) ARTMENT INOVIO receives $71 million from DoD to scale up manufacture of CELLECTRA 3PSP and procurement of CELLECTRA® 2000 (6/23) OF INOVIO announces positive interim Phase 1 data for INO-4800 (6/30); durable antibody and T cell responses in NHPs challenged with SARS-COV-2 (7/30) Phase 1/2 trials begin in South Korea, China SEPTEMBER 2020 Phase 2/3 trials expected to begin* ONGOING INO-4800 COVID-19 DNA vaccine production and scale up underway* 13 *Pending appropriate regulatory guidance and external funding#14INOVIO INO-4800 Rapid Response Species . • • Mouse • Guinea Pig (ID delivery) Rabbit (full human dose) . NHP (immunogenicity/challenge) . Ferret (challenge) CSIRO First Subject Treated in Phase 1 Trial April 6th, 2020 о 2/02 2/09 2/16 2/23 3/01 3/08 3/15 3/22 3/29 4/06 4/10 5/20 6/30 7/30 nature COMMUNICATIONS Feb 4th Submitted In vitro expression data XXXX THE WISTAR INSTITUTE ● T cell data Ab data Immunization ACE2/Spike blocking Biodistribution nature COMMUNICATIONS Pseudovirus neut. Public Health England Published Live virus neut. INOVIO POWERING DNA MEDICINES#15INO-4800 Demonstrates Durable Efficacy, Safety; Only COVID-19 Vaccine With No Adverse Events > Grade 1 TRIALS: INO-4800 Human Clinical Study: Interim findings (Week 6 efficacy and Week 8 safety) • Protect against SARS-CoV2 virus that causes COVID-19 Target Spike protein Phase 1 study (Initial 2 cohorts reported) 100% (38 out of 38) of trial participants demonstrated overall immunological responses through week 6 Non-Human Primate (NHP) Study: 17-week findings (13 weeks after 2nd dose) Challenge study Durable antibody and T cell responses for >4 months after initial dose Demonstrated binding and neutralizing antibodies and T cell immune responses Memory T and B cell responses reduced viral loads, faster clearance in lungs, nasal passages 40 healthy volunteers age 18-50 X40 1 mg and 2 mg cohorts, 2 doses (Weeks 0 and 4) x10 Safe and well tolerated, no SAEs through Week 8 Trial expanded with older participants, 18 and older and added dose arm of 0.5 mg 5 rhesus macaques received INO-4800, 5 received placebo 2 doses (Weeks 0 and 4) Challenge with SARS-CoV-2 (Week 17) Neutralizing antibodies against early virus and dominant G614 mutant variant No antibody-dependent enhanced disease events 15 INOVIO POWERING DNA MEDICINES#1616 Clinical Development Strategy for INO-4800 ☐ US - Phase 1 study of INO-4800 under US IND Initial funding of up to $9M awarded by CEPI Rapid start of FIH study in young, healthy population; expanded in older adults Preliminary safety and robust immune response data announced in late June ☐ Ex-US Studies in China and Korea ☐ Collaborations formed between INOVIO and Advaccine in China, as well as IVI in Korea to build global consortium for joint clinical development $7.3 million from CEPI to support the Korea Phase 1/2a trial initiated in June 2020 ☐ Phase 1 study in China also initiated ☐ Phase 2/3 Efficacy Study in the US ☐ Study protocol being developed to assess the efficacy for prevention of COVID-19 in high-risk population Expected to start in September pending regulatory approval INOVIO POWERING DNA MEDICINES#17INOVIO-Led Global Coalition to Advance INO-4800 & Commercial Device (CELLECTRA 3PSP) THE CEPI DEPARTMENT YUNITED STATES OF OF DEFENSE AMERICA BILL & MELINDA GATES foundation 17 WISTAR INSTITUTE Advaccine Thermo Fisher SCIENTIFIC International IVI Vaccine Institute ology BIOSERVICES CSIRO Public Health England DEFENSE THREAT REDUCTION UNITED STATES AGENCY OF AMERICA Perelman School of Medicine UNIVERSITY of PENNSYLVANIA INOVIO POWERING DNA MEDICINES#1818 HPV-Related Programs IXI#19HPV-Associated Diseases Market Overview Years to progression HPV-associated conditions per year in US: HPV INFECTION • • 80M Americans currently infected with HPV 14M new infections annually ~7M high-risk HPV infections (HPV 16/18) LOW-GRADE DYSPLASIA • Cervical: 1.1M to 1.7M HIGH-GRADE DYSPLASIA . CANCER . . . • Cervical: ~195,000 . . Vulvar: >25,000 • Anal: >14,000 Cervical: 12,000 HPV-associated H&N: 18,000 2 Anal: 6,500 Vulvar: 4,000 - 19 Sources: US CDC (2018) HPV and Cancer, available at: https://www.cdc.gov/cancer/hpv/statistics/cases.htm (accessed July 22, 2019); Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, Copeland G, Cozen W, Peters ES, Huang Y, Saber MS, Altekruse S, Goodman MT; HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015 Apr 29;107(6):djv086; Inovio Pharmaceuticals, internal estimates from published data (2015-16, 2017-18); US CDC, personal communication (2015); NCI SEER Cancer Stat Facts: Cervix Uteri, Vulvar, and Anal Cancers - https://seer.cancer.gov/statfacts (accessed 2017-18); *Measured as: Genital Warts - Initial Visits to Physicians' Offices, United States, 1966-2014. Fig. 47; Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003 Aug;127(8):946-9; US CDC. Genital HPV Infection - Fact Sheet. INOVIO POWERING DNA MEDICINES#2020 Published VGX-3100 Phase 2b Study Achieves All Primary and Secondary Endpoints Phase 2b Endpoints (n=167) Primary: Secondary: VGX-3100 Specific T Cells¹ 800 600 400 200 Regression to CIN1 or Normal 49.5% P=0.017 Regression of CIN3 & HPV to normal Regression to Normal AND Virological Clearance 40.2% P=0.003 T Cell Responses Measured in Blood * * * * Pre VGX-3100 Placebo 5 10 15 20 25 30 35 40 Study Week Treatment at wks 0, 4, & 12 *Statistically significant; bars are 95% CI Trimble et al. Lancet 2015 Post Week 36 Week 0 Increased and persistent presence of CD8+ cells (24 weeks post-last dose) IHC Staining: HPV IHC Staining: CD8 + CD8+ T Cell Infiltration INOVIO POWERING DNA MEDICINES#2121 VGX-3100 Phase 3 Program: HPV-Associated Cervical HSIL/ Precancerous Dysplasia TRIAL: VGX-3100 • Targets HPV 16/18 subtypes; E6/E7 oncogenes Treats high-grade squamous intraepithelial lesions (HSIL) Phase 3 consists of 2 studies in parallel: REVEAL1 (primary) n=198 - Enrollment Closed Study follow-up through week 88 (as in P2b) Topline efficacy data expected by 4Q 2020 FIRST treatment for HPV infection of the cervix FIRST non-invasive treatment for cervical pre-cancer 2:1 Randomized (2:1), double- blind, placebo-controlled REVEAL2 (confirmatory) n=198 - Now Enrolling Study follow-up through week 40 Primary endpoint: Regression of HSIL (CIN2/3) AND clearance of HPV 16/18 in the cervix 88-8 Dosing: month 0, 1, 3 (as in P2b) mo.9 Primary endpoint measured at month 9 (as in P2b) INOVIO POWERING DNA MEDICINES#22VGX-3100 Phase 2 Studies in HPV-Associated Vulvar and Anal HSIL/Precancerous Dysplasias • Target HPV 16/18 subtypes; E6/E7 oncogenes TRIALS: VGX-3100 • Treat high-grade squamous intraepithelial lesions (HSIL) Precancerous Vulvar Dysplasia: Interim findings (6 months after start of treatment) 22 Phase 2 open-label study x33 33 women enrolled Interim data reported for 10 Decrease in lesion area: 80% of patients Resolution of vulvar dysplasia: 20% of patients Non-detectability of HPV 16/18: 20% of patients Phase 2 open-label study x23 23 patients enrolled Precancerous Anal Dysplasia: Interim findings (6 months after start of treatment) Clearance of lesions: 50% of patients Interim data reported for 20 Decrease in number of lesions: 75% of patients INOVIO POWERING DNA MEDICINES#23INOVIO and QIAGEN Developing Biomarker to Optimize Patient Selection 23 23 QIAGEN INOVIO In 2Q 2019, INOVIO entered into collaboration with QIAGEN to co-develop a liquid biopsy-based pretreatment commercial test kit to guide patient selection for VGX-3100: • • Aimed to produce an accurate test that would increase absolute efficacy of VGX-3100 among HPV-infected women who have progressed to cervical HSIL (pre-cancer) Commercialization of a CDx test concurrently with VGX-3100 could enhance market adoption of this first-in-class DNA medicine INOVIO POWERING DNA MEDICINES#24Recurrent Respiratory Papillomatosis (RRP) Caused by HPV 6 and 11 Areas affected by Recurrent Respiratory Papillomatosis (RRP) Larynx (voice box) Vocal folds • Rare, orphan disease with ~15,000 total active cases within the U.S., where virtually all of those require surgical procedures • • • . ~6,000 new cases per yr. in the U.S. HPV-associated disease; caused by HPV 6 and 11 Growths can lead to life-threatening airway obstructions SoC is lifelong surgery (repeated/multiple times a yr) Currently, disease is incurable and can only be treated by surgery to remove tumors, which temporarily restores the airway RRP may occur in adults as well as in children who are thought to have contracted the virus during childbirth 24 24 Trachea (windpipe) Sources: RRP Foundation; Venkatesan et al. Otolaryngol Clin North Am 2013; Ivancic et al. Laryngoscope Investigative Otolaryngol; www.nidcd.nih.gov/health/recurrent-respiratory-papillomatosis; Derkay et al Arch Otolaryngol Head Neck Surg (1995); Armstrong et al Arch Otolarygol Head Neck Surg (1999); Marsico et al STDs (2014). INOVIO POWERING DNA MEDICINES#25INO-3106 Pilot Study in RRP - Completed TRIAL: INO-3106 (for HPV 6-caused RRP) Phase 1 pilot, single-site, clinical study x2 Enrolled 2 adult patients with RRP, HPV 6+ 4 doses of vaccine, 3 weeks apart on Day 0, Weeks 3, 6, 9 4 CELLECTRA-delivered INO-3106 (only for HPV 6) plasmid encoded antigens Two RRP patients had prior surgeries every 6 months After receiving 4 doses, 1 patient has gone >915 days without surgery, and the second went 584 days without surgery Open-label Phase 1/2 study to evaluate efficacy, safety, tolerability, and immunogenicity of INO-3107 (for HPV 6 and 11) 25 25 Published in Vaccines (MDPI); entitled "Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis"; January 23, 2020. INOVIO POWERING DNA MEDICINES#26INO-3107 Phase 1/2 Study in RRP - IND Accepted; Granted Orphan Drug Designation TRIAL: INO-3107 (for HPV 6 and/or 11-caused RRP) Granted Orphan Drug Designation Phase 1/2 open- label, multicenter clinical study 26 26 x63 Target enrollment 4 doses of vaccine, 3 weeks apart on Day 0, Weeks 3, 6, 9 CELLECTRA-delivered INO-3107 plasmid encoded antigens Enrollment criteria: Subjects who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma(s) Primary endpoint: A doubling or more in the time between surgical interventions following the first dose of INO-3107 relative to the frequency prior to study therapy INOVIO POWERING DNA MEDICINES#2727 MEDI0457 for HPV-Related Cancers in Partnership with AstraZeneca AstraZeneca $ INOVIO . MEDI0457 (formerly INO-3112) = VGX-3100 + INO-9012 (IL-12 plasmid) . • In 2015, AstraZeneca acquired exclusive rights to MEDI0457 · $27.5M upfront • ~$250M in potential development and commercial milestones . • Double-digit tiered royalties on MEDI0457 sales AstraZeneca is evaluating MEDI0457 in combination with its PD-L1 checkpoint inhibitor, durvalumab, in HPV-associated cancers INOVIO POWERING DNA MEDICINES#28MEDI0457 Potential to Treat Head and Neck Cancer Demonstrated in Phase 1 Trial Cohort 1 HPV 16/18+ HNSCC undergoing definitive surgery (n=5) Immunotherapy is administered before and after surgery Surgery > 4 months Cohort 2 HPV 16/18+ HNSCC undergoing definitive/adj chemoradiation (n=20) Immunotherapy is administered 2 months after completion of chemoradiation Study Treatment: MEDI0457 Follow up for 6 months post last dose Primary: Safety and MEDI0457: 6 mg of VGX-3100 + 1 mg of INO-9012 In Cohort 1, if time allows, up to 2 treatments can be administrated prior to surgery, but total 4 treatments are scheduled tolerability of DNA based immunotherapy Secondary: Cellular and humoral immune responses Exploratory: Anti-tumor response and progression. free survival 28 INOVIO POWERING DNA MEDICINES#2929 29 CD8+ T Cell Infiltration into Tumor Following MEDI0457 Treatment Post MEDI0457 Pre MEDI0457 Pt: 045-509 Pt: 045-524 Robust antigen-specific CD8+ killer T cell responses observed in 20/22 90.1% of patients (both tumor tissue and peripheral blood) Aggarwal et al Clinical Cancer Research 2018 "Cold" "Hot" CD8+ T Cell Infiltration INOVIO POWERING DNA MEDICINES#30MEDI0457 Phase 1 Study Demonstrates Complete Response Series: 3 Series: 3 Image 38 of 109 Image 43 of 107 IPI (Top image) CT neck with IV contrast demonstrating partial response pre- and 6 weeks post-nivolumab. (Bottom image) PET scan images pre- and 6 weeks post-nivolumab. 30 Published in Clinical Cancer Research (CCR) 2018 . • . Phase 1 study of MEDI0457 (VGX-3100+ IL-12) in 22 HPV+ H&N cancer patients Robust antigen-specific CD8+ killer T cell responses observed in 20/22 - 90.1% of patients (both tumor tissue and peripheral blood) 4 progressed over several year period exhibiting recurrence with metastatic disease; treated with PD-1 2/4 (50%) show complete response to PD-1 therapy and remained tumor free for 2+ years 50% CR rate compares well in metastatic HPV+ H&N: • • 4% CR rate (8/192) by KEYTRUDA alone 3% CR rate (6/240) by OPDIVO alone AstraZeneca conducting Phase 2 studies combining MEDI0457 and durvalumab (PD-L1 inhibitor) INOVIO POWERING DNA MEDICINES#3131 MEDI0457 for HPV-Associated Head & Neck Cancer in Phase 1b/2a in Partnership with AstraZeneca TRIAL: MEDI0457 (VGX-3100 + IL-12) AstraZeneca >> Phase 1b/2a open label study for metastatic HPV+ HNSCC with persistent or recurrent disease after chemotherapy treatment Combination with AstraZeneca's PD-L1 checkpoint inhibitor (durvalumab) Primary Endpoints: Safety, tolerability Secondary Endpoints: Immunogenicity, ORR, PFS, Disease CR, OS ENROLL x35 Completed enrollment of 35 subjects in August 2019 TUMOR CORE BIOPSY AT SCREEN & WEEK 10 ↓ Planned Dosing Schedule: durvalumab at Weeks 4, 8 and 12 and then every 4 weeks until disease progression, unacceptable toxicity or withdrawal of consent 1. 3 3. 5. 7. 10. 12. 16. 20. Planned Dosing Schedule: MEDI0457: Weeks 1, 3, 7 and 12 and then every 8 weeks until disease progression, unacceptable toxicity or withdrawal of consent INOVIO POWERING DNA MEDICINES#3232 32 Immuno-Oncology Programs. X#3333 INO-5401 for Newly Diagnosed GBM in Phase 1/2 Study in Collaboration with Regeneron TRIAL: INO-5401 (encoding tumor-associated antigens: hTERT, WT1, PSMA) Phase 1b/2 open label study for newly diagnosed glioblastoma (GBM) ○ Combination with Regeneron's PD-1 checkpoint inhibitor cemiplimab (LibtayoⓇ) Primary Endpoints: Safety, tolerability Secondary Endpoints: Immunological impact, PFS and OS x32 Cohort A: MGMT Promoter Unmethylated: 32 patients *x20 Cohort B: MGMT Promoter Methylated: 20 patients Resection RT within WK 3 INO-5401 INO-9012 DOSE 2 WK 6 WK 9 INO-5401 INO-9012 DOSE 3 INO-5401 INO-9012 DOSE 4 Screening DAY O INO-5401 INO-9012 DOSE 1 RT +TMZ 3 WEEKS 42 days of resection TMZ WK 12 * WK TMZ 15 TMZ Cemiplimab every 3 weeks until disease progression *TMZ 6 Cycles (Cohort B only) WK 18 INO-5401 + INO-9012 continues every 9 weeks until disease progression INOVIO POWERING DNA MEDICINES#3434 • INO-5401 Results: Promising 12-Month Overall Survival Data and 6- Month Progression-Free Survival Data; OS18 Data in 4Q2020 Overall survival at 12 months (OS12) to be presented at ASCO 2020 Annual Meeting • MGMT Promoter Unmethylated OS12 of 84.4% • MGMT Promoter Methylated OS12 of 85% • • Compares favorably with historical value of 65% Previously reported PFS6 at SITC 2019 . . MGMT Promoter Unmethylated PFS6 of 75% MGMT Promoter Methylated PFS6 of 80% Compares favorably with historical value of 40-60% IFN- SFU/10€ PBMC Immunology Output to Date All subjects 10000- 1000- 100- 10- 1 WT1 PSMA hTERT INO-5401 n=11 Baseline Subjects with sample to week 24 10000- 1000- 100- 10- Week 9 WT1 PSMA n=8 hTERT INO-5401 Week 21 . Majority of patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401 • Combination of INO-5401 + INO-9012 with cemiplimab, with radiation and temozolomide, is promising . Overall survival results (OS18) will be presented 4Q 2020 Several patients have experienced pseudo-progression, with progression by RANO criteria and radiographic evidence of progression on MRI, without evidence of tumor on repeat biopsy INOVIO POWERING DNA MEDICINES Stupp et al. N Eng J Med 2005; Hegi et al. N Eng J Med 2005; Stupp et al. N Eng J Med 2009#3535 55 INO-5151 Phase 2 Prostate Cancer Combination Study TRIAL: INO-5151 (encoding tumor-associated antigens: PSA, PSMA) Phase 2 study (PORTER) for metastatic castration-resistant prostate cancer x45 Three cohort, 45-patient platform study, INO-5151 in Cohort C Cohort C-15 patients INO-5151 (DNA immunotherapy) CDX-301 (FLT3 ligand) from Celldex Therapeutics Nivolumab (anti-PD-1) from Bristol-Myers Squibb PICI/CRI will fund & execute the clinical study PICI PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY CANCER RESEARCH INSTITUTE INOVIO POWERING DNA MEDICINES#3636 Management & Financials#3737 Experienced Executive Team and Board of Directors • • J. Joseph Kim, Ph.D. President & CEO Decades of biotech/pharma management Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D Board of Directors Peter Kies CFO Jacqueline Shea, Ph.D. COO • Ernst & Young •. Former CEO/COO of Aeras • Experience with growth companies • Held management positions at Emergent BioSolutions and Microscience Ltd. • Laurent Humeau, Ph.D. CSO Extensive R&D leadership exp. in vaccine, cell and gene therapy developments in private biotech and mid-cap companies Led Translational Research, Human Therapeutics Division for Intrexon Simon X. Benito Chairman of the Board, Former SVP, Merck Vaccine Division J. Joseph Kim, Ph.D. President & CEO, INOVIO Pharmaceuticals Ann. C. Miller, M.D. Former Head of Sanofi Oncology Global Marketing Jay Shepard Former President & CEO, Aravive David B. Weiner, Ph.D. Executive VP, Director, Vaccine Center, The Wistar Institute Wendy L. Yarno, Ph.D., Former Executive VP and Chief Marketing Officer, Merck Lota S. Zoth Former CFO, MedImmune INOVIO POWERING DNA MEDICINES#3838 Strong Balance Sheet to Support Critical Milestones NASDAQ:INO $371.7M Cash and short-term investments As of June 30, 2020 168M Common stock shares outstanding As of August 10, 2020 VGX-3100 ✓ 1Q20: Report interim data from Phase 2 VIN/AIN clinical trials 4Q20: REVEAL 1 Phase 3 top-line efficacy & safety data 2H20: Report full data from Phase 2 VIN/AIN clinical trials MEDI0457 2020: Interim data from AZ on MEDI0457 Phase 2 study in HNSCC INO-3107 1H20: Initiate Phase 1/2 trial of INO-3107 for RRP (HPV6 and 11) ✓ July 2020: Received Orphan Drug Designation from FDA INO-5401 ✓ 2Q20: OS12 data from Phase 1/2 GBM clinical trial (INO-5401 plus LibtayoⓇ) 4Q20: OS18 data from Phase 1/2 GBM clinical trial (INO-5401 plus LibtayoⓇ) INO-4800 ✓ April 2020: Initiate Phase 1 trial of INO-4800 for COVID-19 Sep 2020: Initiate Phase 2/3 trials of INO-4800 for COVID-19 Platform Development 2020: CEPI-funded INO-4700 against MERS into Phase 2 in Middle East & Africa 2020: Interim Phase 1 results from first-in-human trial of dMAb TM plasmid candidate INO-A002 (for preventing or treating Zika virus infection) INOVIO POWERING DNA MEDICINES#39INOVIO DNA Medicine Value Proposition NASDAQ:INO • • Validated Technology Platform . • • Demonstrated Phase 2b clinical efficacy of lead asset VGX-3100 Validated safety data in >2,000 patients and >7,000 administrations with CELLECTRA smart device, and consistent demonstration of high levels of T cell and antibody immune responses Well-protected with over 1,000 issued and pending patents Over $210M in non-dilutive funding since 2009 Partnerships with major pharma and organizations: CEPI BILL&MELINDA GATES foundation AstraZeneca DARPA DEPARTMENT OF DEFENSE UNITED STATES AMERICA OF Multiple catalysts in 2020 • • INO-5401 Phase 2 GBM OS18 data VGX-3100 Phase 3 cervical precancer topline data readout • INO-4800 Phase 1 safety/immunogenicity publication/Conduct Phase 2/3 39 PICI PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY REGENERON NIH INOVIO POWERING DNA MEDICINES#4040 40 IN VIO POWERING DNA MEDICINES™ INOVIO POWERING DNA MEDICINES#4141 Appendix IXI#42INOVIO DNA Medicines Will Meet Urgent Health Needs Worldwide JOURNAL of the JNCI NATIONAL CANCER INSTITUTE 42 HPV-Related Diseases • • Nearly 80M Americans are currently infected with HPV; ~14M become infected each year ~35k Americans get an HPV-attributable cancer per year, including head and neck and cervical, anal, penile and vulvar cancers ~23% of Americans age 18-59 have genital infections with 21 high-risk HPV genotype (e.g., HPV 16, HPV 18), which can lead to cervical, anal, head and neck, and other cancers; no current medicine to destroy/clear the virus ~4% of Americans age 18-69 have oral infection with ≥1 high-risk HPV genotype Other HPV genotypes (6/11) can cause debilitating conditions such as Recurrent Respiratory Papillomatosis (RRP), rare and potentially life-threatening in children and adults; only current treatment is multiple, lifelong surgeries HealthDay HPV Blamed for Rising Rates of Anal Cancer Nov 20, 2019, 12:00 pm By Steven Reinberg HealthDay ReporterWEDNESDAY, Nov. 20, 2019 (HealthDay News) Anal cancer rates have surged in the past 15 years, and the sexually transmitted human papillomavirus (HPV) may CAN health "People New Study Reveals a Rise in Anal Cancer Rates and Deaths in the United States A majority of the cases observed by researchers were caused by the human papillomavirus By Claudia Harmata November 20, 2019 02:04 PM f FB Twitter LOOK LELESS NAS P People Η ΠΑΕ 11 сара σ = The Washington Post The Washington Post Derne D Amer Medical Mysteries Top tools Anal cancer rates and deaths are climbing in the US, study says By Kristen Rogers, CNN Updated 10-27 PM ET, Tue November 19, 2019 PIAGET THOUSANDS IRIT ARDS Heineken OF CLICKS OR ONE GI Mome Try 1 month for SL A toddler's dwindling voice was chalked up to acid reflux. Her problem was far more serious. INSIDE edition A Tax Solution Woman With Raspy Voice Has Had More Than 300 Surgeries to Treat Rare Vocal Cord Disease HEALTH 235PM PDT. April 11, 20 JOHANNA LI INOVIO POWERING DNA MEDICINES#43INOVIO DNA Medicines Will Meet Urgent Health Needs Worldwide (continued) Cancer (non-HPV associated) • >11,000 people in U.S. get glioblastoma (GBM, rare and most aggressive form of brain cancer) each year; 23,000 people in U.S. have GBM REGENERON Infectious Diseases (non-HPV associated) · HIV NIH NIAID TRIALS HIV VACCINE NETWORK . Ebola DARPA • MERS 진원생명과학(주) GENE Science CEPI • most common cancer among men except for skin cancer PICI PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY CANCER RESEARCH INSTITUTE ~3.1M men in U.S. have prostate cancer, the • Zika 진원생명과학(주) BILL&MELINDA GENE GeneOne Life Science GATES foundation . Lassa Fever • COVID-19 CEPI CEPI BILL & MELINDA GATES foundation 43 INOVIO POWERING DNA MEDICINES#44INOVIO's Technology Delivering Precisely Designed Plasmids with Proprietary Smart Devices INOVIO's DNA medicine powers a patient's immune system to generate functional antibodies and killer T cells. Colls Syringe Electrical pulses DNA vaccine Cell membrane Temporary openings Nucleus DNA vaccine Syringe inserted into selected muscle or skin tissue injects the DNA vaccine. Controlled, milli-second electrical pulses are applied to the needle electrodes. which then form an electric field. The electrical field creates temporary openings in the cell membrane, allowing significantly greater amounts of the DNA vaccine to enter cells. Lymph node Immune cells Antigen- presenting cell Antibodies Killer T cells Lymph node 44 In the lymph node, the interaction of antigen-presenting cells and other immune cells results in antibodies that can prevent future infections or killer T-cells that can clear already-infected cells. Antigen-presenting cells engulf the antigens and carry them to lymph nodes. The cell membrane reseals and the trapped DNA causes the cell to produce the antigen coded by the DNA. Inovio Pharmaceuticals, Inc, 2010. All Rights Reserved. INOVIO POWERING DNA MEDICINES#45Precise Design + Intracellular Delivery = Improved Immune Responses 45 45 Muscle + GFP GFP With EP Display of GFP (green fluorescent protein) gene expression after CELLECTRA® delivery into rabbit muscle Muscle + GFP GFP No EP INOVIO POWERING DNA MEDICINES#46Innovation in the Delivery of Syn ConⓇ DNA Medicine SynConⓇ 46 46 CELLECTRAⓇ-5PSP Intramuscular • • 13, 19, 25mm electrodes • In clinical use Skin Skeletal Muscle CELLECTRAⓇ-3P Intradermal - Surface EP (SEP) • • . ⚫ Surface Noninvasive 4x4 electrode array Specifically targets epidermis In late-stage preclinical development • minimally invasive • • • 3mm electrodes . • In clinical use Epidermis Full Thickness Hair Follicle 3 mm Dermis Subdermis Surface Hair Follicle 00 - .mm INOVIO POWERING DNA MEDICINES#4747 CELLECTRAⓇ Platform CELLECTRA-5PSP Intramuscular EP CELLECTRA-3P Intradermal EP CELLECTRA-3P technology in a hand-held portable device CELLECTRAⓇ 2000 EP Technology - Track record of success in the clinic . . . • > 2,000 human subjects and >7,000 doses CELLECTRA® 5PSP device developed to support Phase 3 and commercial launch Phase 2 efficacy data combining DNA vaccine and EP Global - Regulatory approval for studies in 6 continents (including Central & Sub-Saharan Africa); both devices CE marked in Europe INOVIO POWERING DNA MEDICINES#48CELLECTRA® 5PSP - INOVIO's First Commercial Smart Device inovio CELLECTRAⓇ 5PSP World's first commercial smart device for DNA medicine - CE Marking in Europe Proprietary smart device currently used in Phase 3 trials Simplified interaction and automated injection using prefilled cartridge Disposable single use array which includes. used drug cartridge Touch screen interface, automated sensors and trigger start Records data file for post-treatment review Data files can be downloaded from system and uploaded to web-based interface Several rounds of Usability Testing that refined development 48 48 Inovio INOVIO POWERING DNA MEDICINES#49Limitations of Other Approaches Viral Vectors - Receptor/cell target based mediated entry • Systemic delivery/local injection. • Preexisting or induced immunity is an issue • Biologic variability of take Immune bias tuned by vector • Hard to re-administer/tissue tropism limits and positives RNA LNP/nanoparticle delivery dependent • - Systemic delivery, localized expression (liver>lung or spleen) Process for manufacture and release work in progress Formulations + RNA follow tissue targeting of the particles/cold chain required, include focus on IV route • DLT observed, low CTL induced, inflammatory 49 49 • High cost of goods double- stranded DNA 0000000 fiber hexon DNA 3030000 penton base penton C single-stranded DMA exon intron RNA Sequence INOVIO POWERING DNA MEDICINES#5050 50 Robust Cellular and Humoral Immune Responses Following Immunization of INO-4800 in Rhesus Monkeys Animal: Treatment: Group Vaccine Delivery Rhesus macaque Day 0 and 28 ID delivery of pDNA 1 PGX9501 ID, 1 site 2 PGX9501 ID, 2 sites SFU/million cells SARS-CoV-2 Spike peptides 300 Prebleed 200. 100 0 T Group 1: 1mg Group 2: 2mg ▪ - - - - Week 2 Group 1: 1mg Group 2: 2mg Group 1: 1mg SARS-COV-2 Spike Pool 1 SARS-COV-2 Spike Pool 2 SARS-COV-2 Spike Pool 3 SARS-COV-2 Spike Pool 4 SARS-COV-2 Spike Pool 5 Week 6 Group 2: 2mg Endpoint titer nCoV S1 1000000 100000- 8 10000- 1000- 100- 10- 1 0.1 T T T 0 2 4 6 0 2 4 6 Week Robust and rapid B and T cell responses in NHPS Dose per immunization 1 mg 2 mg Group 1: 1mg Group 2: 2mg LO 5 n INOVIO POWERING DNA MEDICINES#5151 HPV-Related Clinical Program Overview Precancerous Dysplasias (VGX-3100) • • Cervical dysplasia: Phase 2b PoC trial demonstrated a complete response in 43 out of 107 patients in regression of high-grade cervical lesions and elimination of HPV infection Vulvar dysplasia: Open-label Phase 2 trial showed 8 out of 10 women had reduction in lesion area; 2 of 10 had no virus at 6 months (interim) Anal dysplasia: Open-label Phase 2 trial showed clearance of precancerous lesions in 10 out of 20 patients, decrease in lesions for 15 of 20 (interim) Head & Neck Cancer (MEDI0457) • • Phase 1 trial for HNSCC, 2 out of 4 patients treated with MEDI0457 and 2 different PD-1 checkpoint inhibitors experienced a long-term complete response for >2 years MEDI0457 is licensed by AstraZeneca and currently in a Phase 1b/2a study in combination with durvalumab (PD-L1 checkpoint inhibitor) RRP (INO-3107) • • Pilot study for Recurrent Respiratory Papillomatosis (RRP) demonstrated a clinical benefit in 2 out of 2 patients by delaying surgery due to lack of tumor recurrence A Phase 1/2 clinical trial for treating RRP with INO-3107, which includes both HPV 6 and HPV 11 antigens, is planned INOVIO POWERING DNA MEDICINES#5252 529 CTLA4 or PD1 + DNA Vaccine Improves Tumor Control & Survival in Challenge Model AMERICAN SOCIETY of Checkpoint Inhibitor Therapies Combined with INOVIO DNA Medicine • Potential to improve response rates, without adding toxicity Tumor infiltration of antigen-specific, functional CD8+ T cells may prime patients for treatment with checkpoint inhibitors and increase response rates Combination studies initiated ⚫ MEDI0457 with AstraZeneca PDL-1 • INO-5401 with Regeneron PD-1 • INO-5151 with BMS PD-1 + Celldex FTL3L (PICI Study) Molecular Therapy Original Article Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT GENE & CELL. THERAPY Elizabeth K. Duperret, Megan C. Wise, Aspen Trautz, Daniel O. Villarreal, Bernadette Ferraro,² Jewell Walters,² Jian Yan, Amir Khan, Emma Masteller, Laurent Humeau, and David B. Weiner' Tumor volume (mm3) Tumor volume (mm3) 800 600- 400- 200 800- 600- 400- 200 20 10 Days elapsed -Naive mTERT alone MTERT CTLA-4 Naive mTERT alone mTERT aPD-1 10 20 Days elapsed Paper published in Molecular Therapy 2017 INOVIO POWERING DNA MEDICINES#5353 53 MEDI0457 (HPV16/18) Induces Robust Anti-Tumor Immunity in Head and Neck Cancer Phase 1 study of MEDI0457 (INO-3112) in 22 HPV+ HNSCC Patients Pre-MEDI0457 Post-MEDI0457 Strong invasion by CD8 T cells into tumors following immunization with MEDI0457 in HPV associated HNSCCa. CD8+ T cell expression Perforin expression Reciprocal Anti HPV18 E7 Endpoint Titer SFU/10° PBMCS Induction of T cells: Quantitative non-cultured ELISpots 4001 350- 300- 250 200- 150 100 50- 0 Baseline Peak Response Induction of Antibodies: Endpoint titers to HPV18 E7 2x103 1x103- 5x102 Aggarwal et al Clinical Cancer Research 2018 1x100 -8888888e- Baseline Most participants respond immunologically to the vaccine AstraZeneca Perelman School of Medicine UNIVERSITY of PENNSYLVANIA THE XXX WISTAR INSTITUTE eeee Peak Response INOVIO POWERING DNA MEDICINES#5454 GBM (Newly-diagnosed) Phase 1/2 Study Trial Treatment (NCT03491683) . ● INO-5401 (3 mg of each WT1, PSMA and hTERT plasmids) combined with 1 mg INO-9012, (total 10 mg of DNA) IM injection followed by EP given every 3 weeks for 4 doses, then every 9 weeks; and Cemiplimab (LIBTAYOⓇ) (350 mg/dose IV every 3 weeks) Chemoradiation Treatment . • Radiotherapy (RT), given in a hypofractionated schedule (40 Gy over 3 weeks) for all patients post surgery Temozolomide (TMZ) concurrent with RT for all patients, and then following RT for 6 cycles in methylated patients only INOVIO POWERING DNA MEDICINES#5555 59 Kaplan-Meier Survivor Function 1.0 GBM-001 Progression-Free Survival at Six Months (PFS6) Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Cohort A: MGMT Unmethylated (mITT): All Available Follow-Up 0.8- 06- 0.4 0.2 0.0 First Quartile: 170 Days Median: Not Evaluable 95% CI: (64) 95% CI Not Evaluable Third Quartile: Not Evaluable 95% CI Not Evaluable 3031 29 3 15 # No at Risk 5 D No of Events T 0 60 120 180 240 300 360 420 Exposure in Days Kaplan-Meier Survivor Function Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Cohort B: MGMT Methylated or Indeterminate (mITT): All Available Follow-Up 1.0 0.8- 0.6- 0.4- 02- 0.0- 20 First Quartile: 184 Days Median: Not Evaluable 95% CI: (40, ) 95% CI: (184,) Third Quartile: Not Evaluable 95% CI Not Evaluable 17 15 Kaplan-Meier Survivor Function 1.0- Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Combined Cohorts A & B (mITT): All Available Follow-Up 0.8- 0.6- 0.4- 0.2- 0.0 No at Risk $2 3 No of Events 240 300 360 e 2 о 60 120 180 Exposure in Days Number of events and number of subjects at risk calculated at 3 monthly internals Data as of 24 October 2018 including reports on s First Quartile: 184 Days Median: Not Evaluable 95% CI: (120) 95% CI Not Evaluable Third Quartile: Not Evaluable 95% CI Not Evaluable 15 No at Risk No of Events 0 60 120 180 240 300 360 Exposure in Days Data as of 24 October 2018 dung porn se Cohort N Subjects N Event-free Subjects PFS6 (%) 95% CI Lower Bound 95% CI Upper Bound Cohort A (MGMT Unmethylated) 32 24 75 56.6 88.5 Cohort B (MGMT Methylated) 20 16 80 56.3 94.3 Both Cohorts Combined 52 40 77 63.2 87.5 Confirmed PD (RANO) = confirmation by consecutive PD scan ≥4 weeks from original PD event, or progressed according to biopsy surgery. Subjects who terminated for any reason prior to 6 months other than PD included as confirmed progressive events, including two (2) subjects in Cohort B who came off-study at week three (3), and declined long-term follow-up. Note: subjects with time to events longer than 6 months included; subjects have different time on study durations. INOVIO POWERING DNA MEDICINES#56Executive Team INOVIO POWERING DNA MEDICINES • • J. Joseph Kim, Ph.D., President & CEO Decades of biotechnology/pharma management Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D Peter Kies CFO • Ernst & Young • Experience with growth companies · Jacqueline Shea, Ph.D., COO Former CEO of Aeras, the leading not-for-profit organization dedicated to developing new tuberculosis vaccines Held management positions at Emergent BioSolutions and Microscience Ltd. Laurent Humeau, Ph.D., CSO • Extensive R&D leadership experience in vaccine, cell and gene therapy developments in private biotech and mid-cap companies Led Translational Research, Human Therapeutics Division for Intrexon 56 56#57Board of Directors 57 555 • Simon X. Benito Chairman, BOD Former Senior Vice President, Merck Vaccine Division J. Joseph Kim, Ph.D. President & CEO, INOVIO • Jay Shepard Former President & CEO, Aravive; Former Executive Partner, Sofinnova Ventures • David B. Weiner, Ph.D. Executive VP, The Wistar Institute; Director, Vaccine Center Ann C. Miller, M.D. • Former Head of Sanofi Oncology Global Marketing • Wendy Yarno Former Chief Marketing Officer, Merck Lota Zoth, CPA Former CFO, MedImmune INOVIO POWERING DNA MEDICINES#5858 Scientific Advisory Board • . David B. Weiner, Ph.D., Chairman "Father of DNA vaccines" Executive VP, The Wistar Institute; Director, Vaccine Center • Anthony W. Ford- Hutchinson, Ph.D. Former SVP, Vaccines R&D, Merck • Oversaw development: SingulairⓇ, JanuviaⓇ, Gardasil®, ZostavaxⓇ, ProquadⓇ and RotateqⓇ • • Stanley A. Plotkin, M.D. Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine Emeritus Professor, Wistar Institute & University of Pennsylvania Rafi Ahmed, Ph.D. • Professor, Department of Microbiology and Immunology, Emory University School of Medicine INOVIO POWERING DNA MEDICINES#5959 59 INOVIO Fully Integrated Capabilities Poised for Rapid Production inovic . Philadelphia Corporate and Operations Site Corporate, Clinical, Regulatory, Compliance, Biostatistics, and Data Management functions ~80 FTE inovio • San Diego Research Center ⚫ Molecular biology, cell biology, and clinical immune monitoring • . Research-grade DNA manufacture capabilities • 6,000 sf dedicated BSL-2 research lab (wet lab and cell culture) • 5,000 sf cGLP labs to process, store, and analyze human clinical trial samples • Well established QA capability • • • • San Diego Device Engineering and Manufacturing Facility Electroporation delivery device and consumable design, engineering, and manufacturing Delivery device testing and distribution • 53,000 sf facility opened in July 2017 ISO 13485 and MDD certified by TÜV America in San Diego ⚫ ~70 FTE . ~50 FTE INOVIO POWERING DNA MEDICINES